AZN vs. TEVA: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at AZN and TEVA, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
AZN dominates in value with a market cap of 432.07 billion USD, eclipsing TEVA’s 18.96 billion USD by roughly 22.78×.
TEVA carries a higher beta at 0.63, indicating it’s more sensitive to market moves, while AZN remains steadier at 0.18.
AZN and TEVA are both ADRs—easy access for U.S. investors to foreign shares without dealing with overseas exchanges.
| Symbol | AZN | TEVA |
|---|---|---|
| Company Name | AstraZeneca PLC | Teva Pharmaceutical Industries Limited |
| Country | GB | IL |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - Specialty & Generic |
| CEO | Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. | Mr. Richard D. Francis |
| Price | 69.68 USD | 16.55 USD |
| Market Cap | 432.07 billion USD | 18.96 billion USD |
| Beta | 0.18 | 0.63 |
| Exchange | NASDAQ | NYSE |
| IPO Date | May 12, 1993 | February 16, 1982 |
| ADR | Yes | Yes |
Performance Comparison
This chart compares the performance of AZN and TEVA over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of AZN and TEVA based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- TEVA shows a negative P/E of -14.61, highlighting a year of losses, whereas AZN at 27.80 trades on solid profitability.
- TEVA shows a negative forward PEG of -1.13, signaling expected earnings contraction, while AZN at 2.50 maintains analysts’ projections for stable or improved profits.
| Symbol | AZN | TEVA |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 27.80 | -14.61 |
| Forward PEG Ratio (TTM) | 2.50 | -1.13 |
| Price-to-Sales Ratio (P/S, TTM) | 3.93 | 1.14 |
| Price-to-Book Ratio (P/B, TTM) | 5.26 | 3.00 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 22.33 | 24.73 |
| EV-to-EBITDA (TTM) | 13.68 | 23.01 |
| EV-to-Sales (TTM) | 4.41 | 2.06 |
| EV-to-Free Cash Flow (TTM) | 25.07 | 44.66 |
Dividend Comparison
AZN delivers a 1.39% dividend yield, blending income with growth, whereas TEVA appears to retain its profits, possibly to fund operations, R&D, or other growth initiatives.
| Symbol | AZN | TEVA |
|---|---|---|
| Dividend Yield (TTM) | 1.39% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of AZN and TEVA, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- AZN’s current ratio of 0.90 signals a possible liquidity squeeze, while TEVA at 1.03 comfortably covers its short-term obligations.
- Both AZN (quick ratio 0.70) and TEVA (quick ratio 0.74) fall below 0.8, meaning their most liquid assets—excluding inventory—aren’t enough to meet short-term obligations. This could force them to rely on receivables, inventory turn, or external financing.
- TEVA’s low interest coverage (0.44) means it doesn't cover interest from operating earnings. AZN (at 7.95) meets its interest obligations.
| Symbol | AZN | TEVA |
|---|---|---|
| Current Ratio (TTM) | 0.90 | 1.03 |
| Quick Ratio (TTM) | 0.70 | 0.74 |
| Debt-to-Equity Ratio (TTM) | 0.77 | 2.71 |
| Debt-to-Assets Ratio (TTM) | 0.30 | 0.44 |
| Interest Coverage Ratio (TTM) | 7.95 | 0.44 |